HUMALOG INSULINA LISPRO 100 U/ML SOLUCION INYECTABLE I.V., S.C. Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

humalog insulina lispro 100 u/ml solucion inyectable i.v., s.c.

asofarma s.a. - insulina lispro (origen adn recombinante) - insulina lispro (origen adn recombinante)....100.00 u

Galvumet New Zealand - English - Medsafe (Medicines Safety Authority)

galvumet

novartis new zealand ltd - metformin hydrochloride 1000mg;  ;  ; vildagliptin 50mg;  ;  ;   - film coated tablet - 50mg/1000mg - active: metformin hydrochloride 1000mg     vildagliptin 50mg       excipient: hyprolose hypromellose iron oxide yellow macrogol 4000 magnesium stearate purified talc titanium dioxide - for patients with type 2 diabetes mellitus (t2dm). galvumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus whose diabetes is not adequately controlled on metformin hydrochloride or vildagliptin alone or who are already treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. galvumet is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea. galvumet is indicated as add-on to insulin as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Losar-Denk 100 tablets film-coated Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

losar-denk 100 tablets film-coated

denk pharma gmbh & co. kg - losartan (losartan potassium) - tablets film-coated - 100mg

Metformin Denk 1000 tablets film-coated Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

metformin denk 1000 tablets film-coated

denk pharma gmbh & co. kg - metformin (metformin hydrochloride) - tablets film-coated - 1000mg

Sitagliptin/Metformin Sandoz 50/1000 sitagliptin (as hydrochloride monohydrate)/metformin hydrochloride 50 mg/1000 mg film coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

sitagliptin/metformin sandoz 50/1000 sitagliptin (as hydrochloride monohydrate)/metformin hydrochloride 50 mg/1000 mg film coated tablet blister pack

sandoz pty ltd - metformin hydrochloride, quantity: 1000 mg; sitagliptin hydrochloride monohydrate, quantity: 56.69 mg (equivalent: sitagliptin, qty mg) - tablet, film coated - excipient ingredients: iron oxide yellow; titanium dioxide; hyprolose; povidone; iron oxide red; sodium lauryl sulfate; triethyl citrate; purified talc; microcrystalline cellulose; sodium stearylfumarate; hypromellose; croscarmellose sodium - sitagliptin/metformin sandoz is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.

Metformin Denk 1000 tablets film-coated Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

metformin denk 1000 tablets film-coated

denk pharma gmbh & co. kg - metformin (metformin hydrochloride) - tablets film-coated - 1000mg

Xigduo XR New Zealand - English - Medsafe (Medicines Safety Authority)

xigduo xr

astrazeneca limited - dapagliflozin propanediol monohydrate 12.3mg equivalent to dapagliflozin 10 mg;  ; metformin hydrochloride 1000mg (with 0.5% magnesium stearate);   - modified release tablet - 10mg/1000mg - active: dapagliflozin propanediol monohydrate 12.3mg equivalent to dapagliflozin 10 mg   metformin hydrochloride 1000mg (with 0.5% magnesium stearate)   excipient: carmellose sodium colloidal silicon dioxide crospovidone hypromellose lactose magnesium stearate microcrystalline cellulose opadry yellow 85f12372 - glycaemic control xigduo xr is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control when treatment with both dapagliflozin and metformin is appropriate (see sections 5.1 and 4.4 for available data on the combination therapy). prevention of hospitalisation for heart failure dapagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease to reduce the risk of hospitalisation for heart failure (see section 5.1 pharmacodynamic properties – clinical efficacy and safety). prevention of new or worsening nephropathy dapagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease for the prevention of new or worsening nephropathy (see section 5.1 pharmacodynamic properties – clinical efficacy and safety).

Xigduo XR New Zealand - English - Medsafe (Medicines Safety Authority)

xigduo xr

astrazeneca limited - dapagliflozin propanediol monohydrate 6.15mg equivalent to dapagliflozin 5 mg;  ; metformin hydrochloride 1000mg (with 0.5% magnesium stearate);   - modified release tablet - 5mg/1000mg - active: dapagliflozin propanediol monohydrate 6.15mg equivalent to dapagliflozin 5 mg   metformin hydrochloride 1000mg (with 0.5% magnesium stearate)   excipient: carmellose calcium colloidal silicon dioxide crospovidone hypromellose lactose magnesium stearate microcrystalline cellulose opadry pink 85f94592 - glycaemic control xigduo xr is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control when treatment with both dapagliflozin and metformin is appropriate (see sections 5.1 and 4.4 for available data on the combination therapy). prevention of hospitalisation for heart failure dapagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease to reduce the risk of hospitalisation for heart failure (see section 5.1 pharmacodynamic properties – clinical efficacy and safety). prevention of new or worsening nephropathy dapagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease for the prevention of new or worsening nephropathy (see section 5.1 pharmacodynamic properties – clinical efficacy and safety).

APIDRA 100 U/ML SOLUCION INYECTABLE S.C. Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

apidra 100 u/ml solucion inyectable s.c.

sanofi aventis deutschland gmbh - insulina glulisina recombinante (equivalente a insulina humana 100u) - insulina glulisina recombinante (equivalente a insulina humana 100u)....3.49mg

SOLIQUA 100 U/ML Y 33 MCG/ML SOLUCION INYECTABLE Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

soliqua 100 u/ml y 33 mcg/ml solucion inyectable

sanofi - aventis groupe - insulina glargina - insulina glargina....100 u/1ml / lixisenatida....33 mcgml